Relevance of TSH Receptor Stimulating and Blocking Autoantibody Measurement for the Prediction of Relapse in Graves’ Disease
Abstract Recently, we demonstrated that higher levels of autoantibodies to the human TSH receptor (TBII) predict relapse of hyperthyroidism in Graves’ disease (GD). The aim of this study was to extend this outcome prediction by dividing TBII into stimulating (TSAb) and blocking (TBAb) TSH receptor a...
Gespeichert in:
| Veröffentlicht in: | Hormone and metabolic research 2005-12, Vol.37 (12), p.741-744 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 744 |
|---|---|
| container_issue | 12 |
| container_start_page | 741 |
| container_title | Hormone and metabolic research |
| container_volume | 37 |
| creator | Schott, M. Minich, W. B. Willenberg, H. S. Papewalis, C. Seissler, J. Feldkamp, J. Bergmann, A. Scherbaum, W. A. Morgenthaler, N. G. |
| description | Abstract
Recently, we demonstrated that higher levels of autoantibodies to the human TSH receptor (TBII) predict relapse of hyperthyroidism in Graves’ disease (GD). The aim of this study was to extend this outcome prediction by dividing TBII into stimulating (TSAb) and blocking (TBAb) TSH receptor autoantibodies. Altogether, ninety patients (81 female, 9 male) were retrospectively analyzed; sixty-four patients (71 %) did not go into remission or relapsed, whereas twenty-six patients (29 %) went into remission (median follow-up: 17.5 months). TSAb and TBAb measurement was performed in a CHO cell bioassay with cAMP readout at the time of their first visit in our outpatient clinic (single point measurement in median 6.5 months after initial diagnosis). In the remission group, eighteen of twenty-six patients (69 %) were TSAb-positive, whereas fifty-three of sixty-four patients (83 %) were TSAb-positive in the relapse group (p = ns). The mean stimulation indices (SI) were 4.1 in the remission group and 12.9 in the relapse group, respectively (p = 0.015). By using a threshold of 10 SI, the specificity for relapse was 96.0 %, as only one in twenty patients with an SI above 10 went into remission during follow-up (PPV 95 %). Most TSAb-positive patients also had high levels of TBII. Neither group showed any difference with respect to blocking type autoantibodies, which were mostly negative in both groups. In summary, high TSAb levels are similar but not superior to TBII for predicting relapse in GD patients. In contrast, TBAb measurement does not add any valuable information in this context. In the clinical routine, TSAb/TBAb measurement may not play an important role for diagnosis or outcome prediction of GD, since sensitive 2
nd
generation TBII assays are easier to perform and offer similar information to the clinician. Bioassays should be reserved for special clinical questions such as Graves’ disease in pregnancy. |
| doi_str_mv | 10.1055/s-2005-921099 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68910606</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68910606</sourcerecordid><originalsourceid>FETCH-LOGICAL-c328t-7a705a0bf81901ba6faa374854068acfaa406a8f7c349d16476b97581d7dbdc03</originalsourceid><addsrcrecordid>eNp1kM1u1TAQRi0EopfCki3yihUBO3H8sywFWqQiUFvW1sSZUJfEvthOpW4Qr8Hr8ST46l6JFavxJ535Rj6EPOfsNWd9_yY3LWN9Y1rOjHlANlx0phGtlg_JhjGum56J7og8yfm2RmG4eEyOuOxU27ZqQ35e4ox3EBzSONHrq3N6iQ63JSZ6VfyyzlB8-EYhjPTtHN33XThZS4RQ_BDHe_oJIa8JFwyFTnWr3CD9knD0rvgYdqX1AmwzUh_oWYI7zH9-_abvfK6L-JQ8mmDO-Owwj8nXD--vT8-bi89nH09PLhrXtbo0ChTrgQ2T5obxAeQE0Cmhe8GkBldTfYCelOuEGbkUSg5G9ZqPahxGx7pj8nLfu03xx4q52MVnh_MMAeOardSGM8lkBZs96FLMOeFkt8kvkO4tZ3Yn3Ga7E273wiv_4lC8DguO_-iD4Qq82gPlxldL9jauKdSv_qfvL2tkizA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68910606</pqid></control><display><type>article</type><title>Relevance of TSH Receptor Stimulating and Blocking Autoantibody Measurement for the Prediction of Relapse in Graves’ Disease</title><source>MEDLINE</source><source>Thieme Connect Journals</source><creator>Schott, M. ; Minich, W. B. ; Willenberg, H. S. ; Papewalis, C. ; Seissler, J. ; Feldkamp, J. ; Bergmann, A. ; Scherbaum, W. A. ; Morgenthaler, N. G.</creator><creatorcontrib>Schott, M. ; Minich, W. B. ; Willenberg, H. S. ; Papewalis, C. ; Seissler, J. ; Feldkamp, J. ; Bergmann, A. ; Scherbaum, W. A. ; Morgenthaler, N. G.</creatorcontrib><description>Abstract
Recently, we demonstrated that higher levels of autoantibodies to the human TSH receptor (TBII) predict relapse of hyperthyroidism in Graves’ disease (GD). The aim of this study was to extend this outcome prediction by dividing TBII into stimulating (TSAb) and blocking (TBAb) TSH receptor autoantibodies. Altogether, ninety patients (81 female, 9 male) were retrospectively analyzed; sixty-four patients (71 %) did not go into remission or relapsed, whereas twenty-six patients (29 %) went into remission (median follow-up: 17.5 months). TSAb and TBAb measurement was performed in a CHO cell bioassay with cAMP readout at the time of their first visit in our outpatient clinic (single point measurement in median 6.5 months after initial diagnosis). In the remission group, eighteen of twenty-six patients (69 %) were TSAb-positive, whereas fifty-three of sixty-four patients (83 %) were TSAb-positive in the relapse group (p = ns). The mean stimulation indices (SI) were 4.1 in the remission group and 12.9 in the relapse group, respectively (p = 0.015). By using a threshold of 10 SI, the specificity for relapse was 96.0 %, as only one in twenty patients with an SI above 10 went into remission during follow-up (PPV 95 %). Most TSAb-positive patients also had high levels of TBII. Neither group showed any difference with respect to blocking type autoantibodies, which were mostly negative in both groups. In summary, high TSAb levels are similar but not superior to TBII for predicting relapse in GD patients. In contrast, TBAb measurement does not add any valuable information in this context. In the clinical routine, TSAb/TBAb measurement may not play an important role for diagnosis or outcome prediction of GD, since sensitive 2
nd
generation TBII assays are easier to perform and offer similar information to the clinician. Bioassays should be reserved for special clinical questions such as Graves’ disease in pregnancy.</description><identifier>ISSN: 0018-5043</identifier><identifier>EISSN: 1439-4286</identifier><identifier>DOI: 10.1055/s-2005-921099</identifier><identifier>PMID: 16372227</identifier><language>eng</language><publisher>Germany</publisher><subject>Adolescent ; Adult ; Autoantibodies - blood ; Biological Assay - methods ; Chi-Square Distribution ; Female ; Follow-Up Studies ; Graves Disease - blood ; Graves Disease - diagnosis ; Graves Disease - immunology ; Humans ; Immunoglobulins, Thyroid-Stimulating - blood ; Male ; Middle Aged ; Original Clinical ; Predictive Value of Tests ; Receptors, Thyrotropin - blood ; Receptors, Thyrotropin - immunology ; Recurrence ; Retrospective Studies ; Statistics, Nonparametric</subject><ispartof>Hormone and metabolic research, 2005-12, Vol.37 (12), p.741-744</ispartof><rights>Georg Thieme Verlag KG Stuttgart · New York</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c328t-7a705a0bf81901ba6faa374854068acfaa406a8f7c349d16476b97581d7dbdc03</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-2005-921099.pdf$$EPDF$$P50$$Gthieme$$H</linktopdf><linktohtml>$$Uhttps://www.thieme-connect.de/products/ejournals/html/10.1055/s-2005-921099$$EHTML$$P50$$Gthieme$$H</linktohtml><link.rule.ids>314,776,780,3004,3005,27901,27902,54534,54535</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16372227$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schott, M.</creatorcontrib><creatorcontrib>Minich, W. B.</creatorcontrib><creatorcontrib>Willenberg, H. S.</creatorcontrib><creatorcontrib>Papewalis, C.</creatorcontrib><creatorcontrib>Seissler, J.</creatorcontrib><creatorcontrib>Feldkamp, J.</creatorcontrib><creatorcontrib>Bergmann, A.</creatorcontrib><creatorcontrib>Scherbaum, W. A.</creatorcontrib><creatorcontrib>Morgenthaler, N. G.</creatorcontrib><title>Relevance of TSH Receptor Stimulating and Blocking Autoantibody Measurement for the Prediction of Relapse in Graves’ Disease</title><title>Hormone and metabolic research</title><addtitle>Horm Metab Res</addtitle><description>Abstract
Recently, we demonstrated that higher levels of autoantibodies to the human TSH receptor (TBII) predict relapse of hyperthyroidism in Graves’ disease (GD). The aim of this study was to extend this outcome prediction by dividing TBII into stimulating (TSAb) and blocking (TBAb) TSH receptor autoantibodies. Altogether, ninety patients (81 female, 9 male) were retrospectively analyzed; sixty-four patients (71 %) did not go into remission or relapsed, whereas twenty-six patients (29 %) went into remission (median follow-up: 17.5 months). TSAb and TBAb measurement was performed in a CHO cell bioassay with cAMP readout at the time of their first visit in our outpatient clinic (single point measurement in median 6.5 months after initial diagnosis). In the remission group, eighteen of twenty-six patients (69 %) were TSAb-positive, whereas fifty-three of sixty-four patients (83 %) were TSAb-positive in the relapse group (p = ns). The mean stimulation indices (SI) were 4.1 in the remission group and 12.9 in the relapse group, respectively (p = 0.015). By using a threshold of 10 SI, the specificity for relapse was 96.0 %, as only one in twenty patients with an SI above 10 went into remission during follow-up (PPV 95 %). Most TSAb-positive patients also had high levels of TBII. Neither group showed any difference with respect to blocking type autoantibodies, which were mostly negative in both groups. In summary, high TSAb levels are similar but not superior to TBII for predicting relapse in GD patients. In contrast, TBAb measurement does not add any valuable information in this context. In the clinical routine, TSAb/TBAb measurement may not play an important role for diagnosis or outcome prediction of GD, since sensitive 2
nd
generation TBII assays are easier to perform and offer similar information to the clinician. Bioassays should be reserved for special clinical questions such as Graves’ disease in pregnancy.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Autoantibodies - blood</subject><subject>Biological Assay - methods</subject><subject>Chi-Square Distribution</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Graves Disease - blood</subject><subject>Graves Disease - diagnosis</subject><subject>Graves Disease - immunology</subject><subject>Humans</subject><subject>Immunoglobulins, Thyroid-Stimulating - blood</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Original Clinical</subject><subject>Predictive Value of Tests</subject><subject>Receptors, Thyrotropin - blood</subject><subject>Receptors, Thyrotropin - immunology</subject><subject>Recurrence</subject><subject>Retrospective Studies</subject><subject>Statistics, Nonparametric</subject><issn>0018-5043</issn><issn>1439-4286</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM1u1TAQRi0EopfCki3yihUBO3H8sywFWqQiUFvW1sSZUJfEvthOpW4Qr8Hr8ST46l6JFavxJ535Rj6EPOfsNWd9_yY3LWN9Y1rOjHlANlx0phGtlg_JhjGum56J7og8yfm2RmG4eEyOuOxU27ZqQ35e4ox3EBzSONHrq3N6iQ63JSZ6VfyyzlB8-EYhjPTtHN33XThZS4RQ_BDHe_oJIa8JFwyFTnWr3CD9knD0rvgYdqX1AmwzUh_oWYI7zH9-_abvfK6L-JQ8mmDO-Owwj8nXD--vT8-bi89nH09PLhrXtbo0ChTrgQ2T5obxAeQE0Cmhe8GkBldTfYCelOuEGbkUSg5G9ZqPahxGx7pj8nLfu03xx4q52MVnh_MMAeOardSGM8lkBZs96FLMOeFkt8kvkO4tZ3Yn3Ga7E273wiv_4lC8DguO_-iD4Qq82gPlxldL9jauKdSv_qfvL2tkizA</recordid><startdate>20051201</startdate><enddate>20051201</enddate><creator>Schott, M.</creator><creator>Minich, W. B.</creator><creator>Willenberg, H. S.</creator><creator>Papewalis, C.</creator><creator>Seissler, J.</creator><creator>Feldkamp, J.</creator><creator>Bergmann, A.</creator><creator>Scherbaum, W. A.</creator><creator>Morgenthaler, N. G.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20051201</creationdate><title>Relevance of TSH Receptor Stimulating and Blocking Autoantibody Measurement for the Prediction of Relapse in Graves’ Disease</title><author>Schott, M. ; Minich, W. B. ; Willenberg, H. S. ; Papewalis, C. ; Seissler, J. ; Feldkamp, J. ; Bergmann, A. ; Scherbaum, W. A. ; Morgenthaler, N. G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c328t-7a705a0bf81901ba6faa374854068acfaa406a8f7c349d16476b97581d7dbdc03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Autoantibodies - blood</topic><topic>Biological Assay - methods</topic><topic>Chi-Square Distribution</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Graves Disease - blood</topic><topic>Graves Disease - diagnosis</topic><topic>Graves Disease - immunology</topic><topic>Humans</topic><topic>Immunoglobulins, Thyroid-Stimulating - blood</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Original Clinical</topic><topic>Predictive Value of Tests</topic><topic>Receptors, Thyrotropin - blood</topic><topic>Receptors, Thyrotropin - immunology</topic><topic>Recurrence</topic><topic>Retrospective Studies</topic><topic>Statistics, Nonparametric</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schott, M.</creatorcontrib><creatorcontrib>Minich, W. B.</creatorcontrib><creatorcontrib>Willenberg, H. S.</creatorcontrib><creatorcontrib>Papewalis, C.</creatorcontrib><creatorcontrib>Seissler, J.</creatorcontrib><creatorcontrib>Feldkamp, J.</creatorcontrib><creatorcontrib>Bergmann, A.</creatorcontrib><creatorcontrib>Scherbaum, W. A.</creatorcontrib><creatorcontrib>Morgenthaler, N. G.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Hormone and metabolic research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schott, M.</au><au>Minich, W. B.</au><au>Willenberg, H. S.</au><au>Papewalis, C.</au><au>Seissler, J.</au><au>Feldkamp, J.</au><au>Bergmann, A.</au><au>Scherbaum, W. A.</au><au>Morgenthaler, N. G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Relevance of TSH Receptor Stimulating and Blocking Autoantibody Measurement for the Prediction of Relapse in Graves’ Disease</atitle><jtitle>Hormone and metabolic research</jtitle><addtitle>Horm Metab Res</addtitle><date>2005-12-01</date><risdate>2005</risdate><volume>37</volume><issue>12</issue><spage>741</spage><epage>744</epage><pages>741-744</pages><issn>0018-5043</issn><eissn>1439-4286</eissn><abstract>Abstract
Recently, we demonstrated that higher levels of autoantibodies to the human TSH receptor (TBII) predict relapse of hyperthyroidism in Graves’ disease (GD). The aim of this study was to extend this outcome prediction by dividing TBII into stimulating (TSAb) and blocking (TBAb) TSH receptor autoantibodies. Altogether, ninety patients (81 female, 9 male) were retrospectively analyzed; sixty-four patients (71 %) did not go into remission or relapsed, whereas twenty-six patients (29 %) went into remission (median follow-up: 17.5 months). TSAb and TBAb measurement was performed in a CHO cell bioassay with cAMP readout at the time of their first visit in our outpatient clinic (single point measurement in median 6.5 months after initial diagnosis). In the remission group, eighteen of twenty-six patients (69 %) were TSAb-positive, whereas fifty-three of sixty-four patients (83 %) were TSAb-positive in the relapse group (p = ns). The mean stimulation indices (SI) were 4.1 in the remission group and 12.9 in the relapse group, respectively (p = 0.015). By using a threshold of 10 SI, the specificity for relapse was 96.0 %, as only one in twenty patients with an SI above 10 went into remission during follow-up (PPV 95 %). Most TSAb-positive patients also had high levels of TBII. Neither group showed any difference with respect to blocking type autoantibodies, which were mostly negative in both groups. In summary, high TSAb levels are similar but not superior to TBII for predicting relapse in GD patients. In contrast, TBAb measurement does not add any valuable information in this context. In the clinical routine, TSAb/TBAb measurement may not play an important role for diagnosis or outcome prediction of GD, since sensitive 2
nd
generation TBII assays are easier to perform and offer similar information to the clinician. Bioassays should be reserved for special clinical questions such as Graves’ disease in pregnancy.</abstract><cop>Germany</cop><pmid>16372227</pmid><doi>10.1055/s-2005-921099</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0018-5043 |
| ispartof | Hormone and metabolic research, 2005-12, Vol.37 (12), p.741-744 |
| issn | 0018-5043 1439-4286 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68910606 |
| source | MEDLINE; Thieme Connect Journals |
| subjects | Adolescent Adult Autoantibodies - blood Biological Assay - methods Chi-Square Distribution Female Follow-Up Studies Graves Disease - blood Graves Disease - diagnosis Graves Disease - immunology Humans Immunoglobulins, Thyroid-Stimulating - blood Male Middle Aged Original Clinical Predictive Value of Tests Receptors, Thyrotropin - blood Receptors, Thyrotropin - immunology Recurrence Retrospective Studies Statistics, Nonparametric |
| title | Relevance of TSH Receptor Stimulating and Blocking Autoantibody Measurement for the Prediction of Relapse in Graves’ Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T09%3A41%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Relevance%20of%20TSH%20Receptor%20Stimulating%20and%20Blocking%20Autoantibody%20Measurement%20for%20the%20Prediction%20of%20Relapse%20in%20Graves%E2%80%99%20Disease&rft.jtitle=Hormone%20and%20metabolic%20research&rft.au=Schott,%20M.&rft.date=2005-12-01&rft.volume=37&rft.issue=12&rft.spage=741&rft.epage=744&rft.pages=741-744&rft.issn=0018-5043&rft.eissn=1439-4286&rft_id=info:doi/10.1055/s-2005-921099&rft_dat=%3Cproquest_cross%3E68910606%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68910606&rft_id=info:pmid/16372227&rfr_iscdi=true |